Search research articles
Contact Us
Filters
Showing results (111-120 of 173) with videos related to
Page
of 18
Sort By:
Journal of Medicinal Chemistry
|
May 12, 2012
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding
Ruud P M Dings, Michelle C Miller, Irina Nesmelova, et al.
Investigational New Drugs
|
January 8, 2014
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
Francois Goldwasser, Sandrine Faivre, Jerome Alexandre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
Sandrine Faivre, Catherine Delbaldo, Karina Vera, et al.
Oral Oncology
|
July 11, 2012
Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue
Sébastien Albert, Muriel Hourseau, Caroline Halimi, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 23, 2016
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers
Sihem Sebbagh, Julia Roux, Chantal Dreyer, et al.
Investigational New Drugs
|
July 14, 2007
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
Jérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, et al.
Investigational New Drugs
|
May 10, 2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Werner Hilgers, Sandrine Faivre, Stéphanie Chieze, et al.
Cancer
|
March 15, 2012
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection
Gabriel G Malouf, Laurence Brugières, Marie-Cécile Le Deley, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
Chiaki Tanaka, Terence O'Reilly, John M Kovarik, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 173) with videos related to
Sort By:
Page
of 18
Journal of Medicinal Chemistry
|
May 12, 2012
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding
Ruud P M Dings, Michelle C Miller, Irina Nesmelova, et al.
Investigational New Drugs
|
January 8, 2014
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies
Francois Goldwasser, Sandrine Faivre, Jerome Alexandre, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 30, 2005
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
Sandrine Faivre, Catherine Delbaldo, Karina Vera, et al.
Oral Oncology
|
July 11, 2012
Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue
Sébastien Albert, Muriel Hourseau, Caroline Halimi, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 23, 2016
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers
Sihem Sebbagh, Julia Roux, Chantal Dreyer, et al.
Investigational New Drugs
|
July 14, 2007
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors
Jérôme Alexandre, Carmen Kahatt, Frédérique Bertheault-Cvitkovic, et al.
Investigational New Drugs
|
May 10, 2006
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors
Werner Hilgers, Sandrine Faivre, Stéphanie Chieze, et al.
Cancer
|
March 15, 2012
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection
Gabriel G Malouf, Laurence Brugières, Marie-Cécile Le Deley, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
April 10, 2019
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma
Sandrine Faivre, Armando Santoro, Robin K Kelley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 12, 2008
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data
Chiaki Tanaka, Terence O'Reilly, John M Kovarik, et al.
Page
of 18